Literature DB >> 15292300

Hyperhomocysteinemia in patients with Cushing's syndrome.

Massimo Terzolo1, Barbara Allasino, Sandra Bosio, Elena Brusa, Fulvia Daffara, Massimo Ventura, Emiliano Aroasio, Gianna Sacchetto, Giuseppe Reimondo, Alberto Angeli, Clara Camaschella.   

Abstract

We evaluated serum homocysteine concentrations and the C677T polymorphism of the gene encoding for methylene tetrahydrofolate reductase, a key enzyme for homocysteine metabolism, in 57 patients with Cushing's syndrome, 41 with active disease, and 16 in remission after successful surgery and 105 blood donors. The patients with active Cushing's syndrome had significantly higher serum homocysteine levels and lower folate concentrations than either the patients in remission or controls. The presence of a statistically significant difference in homocysteine concentrations among the three groups was confirmed after adjustment for confounding variables. In a multiple regression model, homocysteine levels were significantly associated with midnight serum cortisol levels (beta = 0.33, P = 0.01), which is the most sensitive marker of endogenous hypercortisolism, and serum folate levels (beta = -0.32, P = 0.02). The distribution of methylene tetrahydrofolate reductase genotypes was not different between patients and controls. In conclusion, active hypercortisolism is associated with hyperhomocysteinemia and reduced serum folate concentrations, whereas the patients in remission have homocysteine concentrations comparable with healthy subjects. Low serum folate concentrations do not fully account for the increase in homocysteine levels that are positively correlated with cortisol levels. Hyperhomocysteinemia may be key to the prothrombotic state and increased cardiovascular risk of Cushing's syndrome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292300     DOI: 10.1210/jc.2004-0079

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

Review 1.  Epigenetic programming and risk: the birthplace of cardiovascular disease?

Authors:  Maria Cristina Vinci; Gianluca Polvani; Maurizio Pesce
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 2.  Cardiovascular risk in Cushing's syndrome.

Authors:  Giorgio Arnaldi; Tatiana Mancini; Barbara Polenta; Marco Boscaro
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

3.  Cortisol levels and metabolic parameters in middle- and advanced- age subjects: associations with age.

Authors:  K Terzidis; A Panoutsopoulos; A Mantzou; P Tourli; G Papageorgiou; K Saltiki; G Tsagalis; C Mara; M Alevizaki
Journal:  J Endocrinol Invest       Date:  2011-07-13       Impact factor: 4.256

Review 4.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 5.  Glucocorticoids and fetal programming part 2: Mechanisms.

Authors:  Vasilis G Moisiadis; Stephen G Matthews
Journal:  Nat Rev Endocrinol       Date:  2014-05-27       Impact factor: 43.330

Review 6.  Impairment of Arterial Compliance in Cushing's Syndrome.

Authors:  Pier Paolo Bassareo; Angela Maria Zedda; Giuseppe Mercuro
Journal:  Eur Endocrinol       Date:  2014-08-28

Review 7.  Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications.

Authors:  G Arnaldi; T Mancini; G Tirabassi; L Trementino; M Boscaro
Journal:  J Endocrinol Invest       Date:  2012-04       Impact factor: 4.256

Review 8.  Nutrition in early life, and risk of cancer and metabolic disease: alternative endings in an epigenetic tale?

Authors:  Graham C Burdge; Karen A Lillycrop; Alan A Jackson
Journal:  Br J Nutr       Date:  2008-12-12       Impact factor: 3.718

Review 9.  Hypercortisolism in obesity-associated hypertension.

Authors:  Amy G Varughese; Oksana Nimkevych; Gabriel I Uwaifo
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

10.  Hyperhomocysteinemia in winter elite athletes: a longitudinal study.

Authors:  P Borrione; F Pigozzi; G Massazza; H Schonhuber; G Viberti; P Paccotti; A Angeli
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.